Concomitant Antihyperalgesic and Antitumor Effects of Gabapentin in a Murine Cancer Pain Model

Abstract

Cancer pain may be the consequence of physical nerve compression by a growing tumor. We employed a murine model to study whether gabapentin was able to regulate tumor growth, in addition to controlling hyperalgesic symptoms. A fluorescent melanoma cell line (B16–BL6/Zs green) was inoculated into the proximity of the sciatic nerve in male C57BL/6 mice. The tumor gradually compressed the nerve, causing hypersensitivity. Tumor growth was characterized via in vivo imaging techniques. Every other day, gabapentin (100 mg/Kg) or saline was IP administered to each animal. In the therapeutic protocol, gabapentin was administered once the tumor had induced increased nociception. In the preventive protocol, gabapentin was administered before the appearance of the positive signs. Additionally, in vitro experiments were performed to determine gabapentin’s effects on cell-line proliferation, the secretion of the chemokine CCL2, and calcium influx. In the therapeutically treated animals, baseline responses to noxious stimuli were recovered, and tumors were significantly reduced. Similarly, gabapentin reduced tumor growth during the preventive treatment, but a relapse was noticed when the administration stopped. Gabapentin also inhibited cell proliferation, the secretion of CCL2, and calcium influx. These results suggest that gabapentin might represent a multivalent strategy to control cancer-associated events in painful tumors.

Bcat1 is controlled by Tsc2/mTORC1 pathway at expression levels and its deficiency together with Bcat2 inactivation suppresses the growth of a Tsc2−/− tumor cell line

“…Although bona fide targets remain elusive at present, Gbp could be one drug option for the treatment of TSC. A recently reported antimelanoma effect of Gbp in a tumor implantation system might offer an existing model for the in vivo analysis to examine the efficacy of Gbp (Brito et al, 2021). Because combined effects with rapamycin were observed in growth assays in vitro, we anticipate that treatment with Gbp and rapamycin at a reduced dose could be a useful strategy for avoiding drug adverse effects.…”

Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancer

“…No study has examined the relationships between MGB and the expression of cell cycle–related molecules, such as cyclins and CDKs. Gabapentin, another voltage-gated calcium channel α2δ unit ligand, inhibits transplant tumor growth of a melanoma cell line 3 ; however, its detailed antiproliferative effects were not described. Although whether the expression of cyclins and CDKs is modulated by MGB through the α2δ1 and α2δ2 subunits is still unclear, our results suggest that the upregulation of cyclins and CDKs would be one of the pro-proliferative mechanisms of MGB.…”

Construction of immunotherapy-related prognostic gene signature and small molecule drug prediction for cutaneous melanoma

“…Several investigations have verified the anticancer effects of Gabapentin in recent years. Gabapentin may achieve anti-melanoma effects in mice by reducing cell proliferation, CCL2 production, and calcium influx ( 68 ). In recent years, it has been demonstrated that thiamine-dependent enzymes (TDEs) are frequently tumor-related targets due to their control of metabolic pathways that are frequently altered in cancer.…”